Literature DB >> 33428606

Exploration of the immune cell infiltration-related gene signature in the prognosis of melanoma.

Yangyang Zeng1,2, Yulan Zeng3, Hang Yin1,2, Fengxia Chen1,2, Qingqing Wang1,2, Xiaoyan Yu1,2, Yunfeng Zhou1,2.   

Abstract

Melanoma is a life-threatening form of skin cancer with an elevated risk of metastasis and high mortality rates. The prognosis and clinical outcomes of cancer immunotherapy in melanoma patients are influenced by immune cell infiltration in the tumor microenvironment (TME) and the expression of genetic factors. Despite reports suggesting that immune-classification may have a better prediction of prognosis compared to the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) TNM-classification, the definition of Immunoscore in melanoma is becoming a difficult challenge. In this study, we established and verified a 7-gene prognostic signature. Melanoma patients from the Cancer Genome Atlas (TCGA) were separated into a low-risk group and a high-risk group using the median risk score. Receiver operating characteristic (ROC) analysis for overall survival (OS) showed that the area under the curve (AUC) was 0.701 for 1 year, 0.726 for 3 years, and 0.745 for 5 years, respectively. Moreover, a nomogram was constructed as a practical prognostic tool, and the AUC was 0.829 for 3 years, and 0.803 for 5 years, respectively. Furthermore, we validated the above results in two datasets from the Gene Expression Omnibus (GEO) database and the relationship between 7-gene prognostic signature and immune infiltration estimated.

Entities:  

Keywords:  biomarkers; immune cell infiltration; melanoma; prognostic signature

Year:  2021        PMID: 33428606     DOI: 10.18632/aging.202279

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  5 in total

1.  Single-Cell Transcriptomic Analysis Reveals a Tumor-Reactive T Cell Signature Associated With Clinical Outcome and Immunotherapy Response In Melanoma.

Authors:  Min Yan; Jing Hu; Yanyan Ping; Liwen Xu; Gaoming Liao; Zedong Jiang; Bo Pang; Shangqin Sun; Yunpeng Zhang; Yun Xiao; Xia Li
Journal:  Front Immunol       Date:  2021-11-05       Impact factor: 7.561

Review 2.  Revisiting miRNA Association with Melanoma Recurrence and Metastasis from a Machine Learning Point of View.

Authors:  Aigli Korfiati; Katerina Grafanaki; George C Kyriakopoulos; Ilias Skeparnias; Sophia Georgiou; George Sakellaropoulos; Constantinos Stathopoulos
Journal:  Int J Mol Sci       Date:  2022-01-24       Impact factor: 5.923

3.  Diffusion-Weighted Imaging Combined with Perfusion-Weighted Imaging under Segmentation Algorithm in the Diagnosis of Melanoma.

Authors:  Chuankui Shi; Peng Ge; Yuping Zhao; Guobao Huang
Journal:  Contrast Media Mol Imaging       Date:  2022-06-27       Impact factor: 3.009

4.  Impaired expression of serine/arginine protein kinase 2 (SRPK2) affects melanoma progression.

Authors:  Mônica Maria Magalhães Caetano; Gabriela Alves Moreira; Maria Roméria da Silva; Gabriela Rapozo Guimarães; Leandro de Oliveira Santos; Amanda de Ambrósio Pacheco; Raoni Pais Siqueira; Flávia Carneiro Mendes; Eduardo De Almeida Marques Da Silva; Abelardo Silva Junior; Juliana Lopes Rangel Fietto; Ângela Saito; Mariana Boroni; Gustavo Costa Bressan
Journal:  Front Genet       Date:  2022-09-23       Impact factor: 4.772

5.  Development and Validation of a CD8+ T Cell Infiltration-Related Signature for Melanoma Patients.

Authors:  Yuan Yuan; Zheng Zhu; Ying Lan; Saili Duan; Ziqing Zhu; Xi Zhang; Guoyin Li; Hui Qu; Yanhui Feng; Hui Cai; Zewen Song
Journal:  Front Immunol       Date:  2021-05-10       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.